FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
- 1											
	OMB Number:	3235-0287									
	Estimated average b	urden									
	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Thackray Helen M.</u>					2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]							(Che	elationship deck all applic	10% Owner				
	C/O IMMUNOGEN, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022								Officer below)	r (give title)		Other (s below)	pecify
830 WINTER STREET (Street) WALTHAM MA 02451				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)											Person	1			
		Tab	le I - Non	-Deriva	ative	e Se	curities	s Ac	quired, D	ispo	sed o	f, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			Execution Date,			Code (Ins	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)				5. Amour Securitie Beneficia Owned F	s ally following	Form	: Direct Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code V	/ A	Amount	(A) or (D)	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Conversion or Exercise Price of Derivative Security			Execution Date, if any		4. Transaction Code (Instr. 8)		of		6. Date Exercisabl Expiration Date (Month/Day/Year)		of Securitie		es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				С	ode	v	(A)	(D)	Date Exercisable		oiration e	Title	Amount or Number of Shares					
Deferred Share Unit	\$0 ⁽¹⁾	06/15/2022			A		10,932		(2)(3)		(3)	Common Stock ⁽³⁾	10,932	\$0 ⁽¹⁾	40,932	2	D	
Stock Option (right to buy)	\$3.37	06/15/2022			A		32,066		(4)	06/1	15/2032	Common Stock	32,066	\$3.37	32,066	6	D	

Explanation of Responses:

- 1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- 2. The deferred share units vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.
- 3. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- 4. The stock options vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.

/s/ Renee Lentini, Attorney-in-Fact

06/17/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.